168 related articles for article (PubMed ID: 35470450)
1. Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis.
Tran L; Yao Z; Xu Z; Vermeulen A
Br J Clin Pharmacol; 2022 Oct; 88(10):4481-4493. PubMed ID: 35470450
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
Yao Z; Hu C; Zhu Y; Xu Z; Randazzo B; Wasfi Y; Chen Y; Sharma A; Zhou H
J Clin Pharmacol; 2018 May; 58(5):613-627. PubMed ID: 29341192
[TBL] [Abstract][Full Text] [Related]
3. Guselkumab for the treatment of palmoplantar pustulosis.
Murakami M
Expert Opin Biol Ther; 2020 Aug; 20(8):841-852. PubMed ID: 32321322
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis.
Chen Y; Miao X; Hsu CH; Zhuang Y; Kollmeier A; Xu Z; Zhou H; Sharma A
Clin Transl Sci; 2022 Mar; 15(3):749-760. PubMed ID: 34854241
[TBL] [Abstract][Full Text] [Related]
5. Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects.
Shao J; Xu Z; Xu Y
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):537-548. PubMed ID: 35442011
[TBL] [Abstract][Full Text] [Related]
6. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group.
Rocamora V; Crespi L; Ferran M; Llamas-Velasco M; Del Alcázar E; Carrascosa JM; Beltran E; Urruticoechea-Arana A; Estebaranz JLL; Vidal D; Riera J; Rodríguez L; Armesto S; Fernández JM; Aparicio G; Pérez S; Porcar S; Montesinos E; Gallardo F
Dermatol Ther; 2022 Nov; 35(11):e15865. PubMed ID: 36175141
[TBL] [Abstract][Full Text] [Related]
7. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
Jauslin P; Kulkarni P; Li H; Vatakuti S; Hussain A; Wenning L; Kerbusch T
Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
[TBL] [Abstract][Full Text] [Related]
9. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
Boehncke WH; Brembilla NC; Nissen MJ
Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of the anti-interleukin-20 monoclonal antibody NNC0109-0012 in healthy volunteers and patients with psoriasis or rheumatoid arthritis.
Lundblad MS; Overgaard RV; Göthberg M; Fjording MS; Watson E
Adv Ther; 2015 Mar; 32(3):228-38. PubMed ID: 25749867
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of pustulotic arthro-osteitis in Korea.
Kim M; Kim M; Kim JW; Kim BR; Youn SW
J Dermatol; 2022 Aug; 49(8):762-768. PubMed ID: 35510638
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis.
Yamamoto T; Fukuda K; Morita A; Kimura T; Morishima H; Goto R; Zheng R; Terui T
J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):2318-2329. PubMed ID: 32173916
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients.
Iwaki Y; Shibata S; Hu C
J Clin Pharmacol; 2022 Feb; 62(2):182-189. PubMed ID: 34382209
[TBL] [Abstract][Full Text] [Related]
16. Pustular Psoriasis and Associated Musculoskeletal Disorders.
Duffin KC; Bachelez H; Mease PJ; Rosen C; Garg A; Zudak E; Elkayam O; Merola JF; Chau J; Kishimoto M; Furer V; Helliwell PS
J Rheumatol Suppl; 2021 Jun; 97():34-38. PubMed ID: 34074664
[TBL] [Abstract][Full Text] [Related]
17. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
[TBL] [Abstract][Full Text] [Related]
18. Palmoplantar pustulosis with psoriatic arthritis ineffective to interleukin-17 inhibitors: two patients successfully treated with upadacitinib.
Zhang ZY; Mi WY; Wang YY; Li W
J Dermatolog Treat; 2023 Dec; 34(1):2280508. PubMed ID: 37968926
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis.
Zhu YW; Mendelsohn A; Pendley C; Davis HM; Zhou H
Int J Clin Pharmacol Ther; 2010 Dec; 48(12):830-46. PubMed ID: 21084039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
